U.S. Markets closed

Johnson & Johnson’s Pulmonary Hypertension Business

Daniel Collins
Johnson & Johnson’s Pulmonary Hypertension Business

In June 2017, Johnson & Johnson’s (JNJ) acquisition of Actelion led to the establishment of its Pulmonary Hypertension segment. In the first quarter, this segment reported revenues of $585.0 million. This included revenues of $361.0 million and $224.0 million from its sales in the US and international markets, respectively.